CoChat

Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis

Open access
Bahji, Anees, Ermacora, Dylan, Stephenson, Callum, Hawken, Emily R., Vazquez, Gustavo · 2021 · The Canadian Journal of Psychiatry

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Objective: We investigated the comparative efficacy and tolerability of augmentation strategies for bipolar depression. Data Sources: We conducted a systematic review and network meta-analysis of 8 electronic databases for double-blind, randomized controlled trials of adjunctive pharmacotherapies for acute bipolar depression. Data Extraction and Synthesis: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and applied the Cochrane risk of bias tool for study quality appraisal. Two reviewers independently abstracted data. We resolved all discrepancies by consensus. Main Outcomes and Measures: Primary outcomes were response and completion of treatment. We estimated summary rate ratios (RRs) and standardized mean differences (SMDs) relative to placebo controls using frequentist random-effects network meta-analysis. Results: We identified 69 trials meeting eligibility criteria (8,007 participants, 42.8 years, 58.0% female). Adjunctive racemic intravenous ketamine, coenzyme Q10, pramipexole, fluoxetine, and lamotrigine were more effective than placebo. Summary RRs for response ranged between 1.51 (95% confidence interval [CI], 1.11 to 2.06) for fluoxetine and 12.49 (95% CI, 3.06 to 50.93) for racemic intravenous ketamine. For completion of treatment, risperidone appeared less tolerable than placebo (RR = 0.59; 95% CI, 0.38 to 0.94), while fluoxetine seemed more tolerable than placebo (RR = 1.13; 95% CI, 1.02 to 1.24). None of the investigated agents were associated with increased treatment-emergent mood switches. Conclusions and Relevance: The evidence for augmentation strategies in bipolar depression is limited to a handful of agents. Fluoxetine appeared to have the most consistent evidence base for both efficacy and tolerability. There remains a need for additional research exploring novel treatment strategies for bipolar depression, particularly head-to-head studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0706743720970857

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 66 · Cited by 31

Research works printed but not linked: 3

  1. Covidence systematic review software. Veritas Health Innovation. Melbourne, Australia. Available at: www.covidence.org
  2. Ghaemi N, 2007, Psychiatry (Edgmont), 4, 56
  3. 10.1034/j.1399-5618.2001.30505.x · doi:10.1034/j.1399-5618.2001.30505.x

Metadata

Authors
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G.
Affiliations
  • University of Calgary (CA)
  • Queen's University (CA)
  • Department of Psychiatry, Queen’s University, Kingston, Ontario, Canada
Corresponding author
Bahji, Anees
Venue
The Canadian Journal of Psychiatry
Published
2020-11-11
Volume
66
Issue
3
Pages
274-288
ISSN
  • 0706-7437 (ISSN-L)
  • 1497-0015
OpenAlex
W3102172621
Cited by
31
References
66
Citations by year
2026: 4 · 2025: 6 · 2024: 7 · 2023: 2 · 2022: 6 · 2021: 6
FWCI
0.58
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • The Canadian Journal of Psychiatry (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
bipolar depression, adjunctive pharmacotherapy, augmentation strategies, intravenous ketamine, fluoxetine, lamotrigine, pramipexole, coenzyme Q10, risperidone, treatment response, treatment completion, tolerability, mood switching
MeSH terms
Anticonvulsants, Bipolar Disorder, Depression, Female, Humans, Male, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis. https://app.cochat.ai/papers/10.1177/0706743720970857
The paper
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2021). Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis. The Canadian Journal of Psychiatry. https://doi.org/10.1177/0706743720970857

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.